Evidence map›Paper›PMID 39522475›Full record

Observational studyMaturitas2025

Associations between the incidence of Fuchs' endothelial corneal dystrophy and menopausal hormone therapy use and exposure to endogenous estrogen.

Amy E Millen, Jing Nie, Yihua Yue, Chris A Andrews, Jean Wactawski-Wende, Robert B Wallace, Aladdin H Shadyab, Sangita P Patel

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Maturitas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amy E MillenDepartment of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, NY, USA. Electronic address: aemillen@buffalo.edu.
Jing NieDepartment of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, NY, USA. Electronic address: jingnie@buffalo.edu.
Yihua YueDepartment of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, NY, USA. Electronic address: yihuayue@buffalo.edu.
Chris A AndrewsDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA. Electronic address: chrisaa@umich.edu.
Jean Wactawski-WendeDepartment of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, NY, USA. Electronic address: jww@buffalo.edu.
Robert B WallaceDepartment of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA. Electronic address: robert-wallace@uiowa.edu.
Aladdin H ShadyabHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA. Electronic address: aladdinshadyab@health.ucsd.edu.
Sangita P PatelDepartment of Ophthalmology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA; Ophthalmology and Research Services, VA Western New York Healthcare System, Buffalo, NY, USA. Electronic address: sppatel@buffalo.edu.

Funding

WOMEN'S HEALTH INITIATIVE - CLINICAL COORDINATING CENTER: TASK AREA B - LONG LIFE STUDY VISIT 2 LIMITED HOME VISIT75N92021D00001 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ANDERSON, GARNET L. · 2021 to 2025
$52.0M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A275N92021D00002 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI WACTAWSKI-WENDE, JEAN · 2021 to 2025
$6.9M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC) - TO EXERCISE OPTION PERIOD ONE (1) AND REVISE CONTRACT ARTICLES.75N92021D00004 · NHLBI · STANFORD UNIVERSITY · PI STEFANICK, MARCIA · 2021 to 2025
$6.5M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC) - TO EXERCISE OPTION PERIOD ONE (1) AND REVISE CONTRACT ARTICLES.75N92021D00003 · NHLBI · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA · 2021 to 2025
$5.0M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC) - TO EXERCISE OPTION PERIOD ONE (1) AND REVISE CONTRACT ARTICLES.75N92021D00005 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI VITOLINS, MARA · 2021 to 2025
$4.2M
Sex disparity and estradiol in Fuchs' endothelial corneal dystrophyK08EY029007 · NEI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI PATEL, SANGITA · 2018 to 2022
$855k
A Study of Estrogen and Body Mass Index in Fuchs’ Endothelial Corneal DystrophyR21EY032544 · NEI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MILLEN, AMY ELIZABETH · 2021 to 2022
$446k
NEI NIH HHS K08 EY029007NEI NIH HHS R21 EY032544NHLBI NIH HHS 75N92021D00001NHLBI NIH HHS 75N92021D00002WHI NIH HHS 75N92021D00003WHI NIH HHS 75N92021D00004WHI NIH HHS 75N92021D00005
6 · The paper itself

Abstract

objectivesEnd-stage Fuchs' endothelial corneal dystrophy is a leading cause of corneal blindness, with a higher prevalence in females than in males. Few modifiable risk factors have been identified. We examined associations between menopausal hormone therapy use (never/past/current), duration of hormone therapy use, estimated lifetime exposure to endogenous estrogen, and serum estradiol with incident Fuchs' endothelial corneal dystrophy in a cohort of postmenopausal women. STUDY

designThis was a prospective analysis in the Women's Health Initiative Observational Study.

main outcome measuresIncident cases of Fuchs' endothelial corneal dystrophy were identified from the Women's Health Initiative Observational Study baseline (1993-1998) through 2019 using Medicare claims data.

resultsIn 22,980 women, 1382 incident cases of Fuchs' endothelial corneal dystrophy (annualized incidence rate and 95 % confidence interval = 5.0 [4.8-5.3] cases per 1000 person-years) were identified. The adjusted hazard ratios and 95 % confidence intervals for Fuchs' endothelial corneal dystrophy were 1.02 (0.88-1.18) and 0.89 (0.79-0.997) for past and current hormone therapy use (vs. never use) at baseline, respectively. Adjusted hazard ratios (95 % confidence interval) were 0.90 (0.79-1.03) and 0.95 (0.84-1.08), p-trend = 0.36, for ≤10 and > 10 years, respectively, of hormone therapy use compared with no use; and the adjusted hazard ratio (95 % confidence interval) was 1.01 (0.88-1.15), p-trend = 0.87, for 46.7-59.0 versus 13.8-41.0 years of estimated lifetime exposure to endogenous estrogen. No statistically significant associations were observed with serum estradiol concentrations in a subset of participants.

conclusionsIn this cohort of postmenopausal women, current hormone therapy use (vs. never use) showed evidence of protection against the development of Fuchs' endothelial corneal dystrophy; however, duration of hormone therapy use, estimated lifetime exposure to endogenous estrogen, or serum estradiol concentrations were not significantly associated with a decreased risk of Fuchs' endothelial corneal dystrophy.

Indexed as

EstradiolEstrogen Replacement TherapyEstrogensFuchs' Endothelial DystrophyPostmenopauseAgedFemaleHumansIncidenceMenopauseMiddle AgedProspective StudiesRisk FactorsUnited StatesEstradiolEstrogensEpidemiologyEstradiolEstrogensEye diseasesFuchs' endothelial corneal dystrophyHormone replacement therapyMenopauseOphthalmology cohort studiesPostmenopause

Identifiers

PMID39522475
PMCPMC11733839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.